Curis Releases DC-0449 Phase II Clinical Trial Results
The trial was conducted by Roche and Genentech, Curis’ collaborator and a wholly owned member of the Roche Group. GDC-0449 is being developed by Roche and Genentech under
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.